Phase 2 (M16-109): Navitoclax + Ruxolitinib in Myelofibrosis (MF)

Phase 2, single-arm, open-label, multicenter study evaluating efficacy, safety and tolerability of navitoclax added to ruxolitinib in patients with MF.

*Estimated enrollment

Key Inclusion Criteria
- Primary or secondary MF
- Ineligible or unwilling to undergo SCT
- Receiving ruxolitinib for at least 24 weeks and on a stable dose of 10 mg BID

Key Exclusion Criteria
- Splenic irradiation within 12 months or prior splenectomy
- Leukemic transformation
- Anti-coagulant therapy
- Prior therapy with BH3 mimetic

Endpoints
- Primary: Percent reduction in splenic volume
- Secondary: PK, safety, reduction in TSS, ORR, anemia response, reduction in BM fibrosis

Navitoclax is an investigational drug that is not approved by the FDA. Safety and efficacy have not been established.

To learn more about these studies, please visit https://ClinicalTrials.gov or email abbvieclinicaltrials@abbvie.com